Skip to main content
. 2023 Feb 10;68:173–180. doi: 10.1016/j.breast.2023.02.003

Fig. 4.

Fig. 4

Cost-effectiveness acceptable curve. The y-axis indicates the likelihood that a regimen is cost-effective across the willingness-to-pay threshold (x-axis). BMN brain metastatic-negative, QALY quality-adjusted life-year, SG sacituzumab govitecan, C chemotherapy.